Mitochondrial function detection method and application thereof, and mitochondrial function detection kit
By detecting the release of mitochondrial DNA into the cytoplasm under high-salt treatment, this method solves the problems of complex and costly mitochondrial function detection equipment in existing technologies, and realizes low-cost and simple-to-operate continuous mitochondrial function assessment.
Patent Information
- Application Number
- CN202510915473.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-02
- Publication Date
- 2025-11-14
AI Technical Summary
Existing methods for detecting mitochondrial function require complex equipment, are costly, and cannot perform continuous testing, thus failing to effectively monitor changes in mitochondrial physiological function.
Mitochondrial function is assessed by detecting the level of mitochondrial DNA release into the cytoplasm after high-salt treatment. Taking advantage of the sensitivity of mitochondrial DNA to high-salt stimulation, conventional experimental equipment and qPCR are used to detect the amount of mitochondrial DNA released for continuous evaluation.
It enables low-cost and simple-to-operate mitochondrial function detection, can continuously monitor the dynamics of mitochondrial DNA release, is suitable for large-scale detection, has high sensitivity, and is suitable for dynamic assessment of mitochondrial function.
Smart Images

Figure CN120945023A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biotechnology, and in particular to a method for detecting mitochondrial function and its application, as well as a mitochondrial function detection kit. Background Technology
[0002] Mitochondria are the cell's energy factories, responsible for producing adenosine triphosphate (ATP) to support normal cellular physiological activities. In addition, mitochondria participate in many key biological processes such as apoptosis, calcium homeostasis regulation, and oxidative stress response, making them one of the most important organelles in the cell. Alterations in mitochondrial function, such as oxidative phosphorylation damage, abnormal energy metabolism, inhibition of apoptosis, impaired autophagy, promotion of immune evasion, and alterations in signaling pathways, can affect the development of diseases. Mitochondrial DNA (mtDNA) differs from nuclear DNA; mtDNA is circular and lacks effective DNA repair mechanisms, making it more sensitive to environmental stress and damage.
[0003] Among related technologies, commonly used methods for detecting mitochondrial function include: 1) Morphological observation: The morphology and structure of mitochondria can be directly observed using transmission electron microscopy (TEM), or the morphology and distribution of mitochondria can be observed using fluorescence microscopy after staining; 2) Detection of mitochondrial reactive oxygen species (ROS) levels: ROS is one of the important indicators of mitochondrial dysfunction, and the level of intracellular ROS can be detected using flow cytometry or fluorescent probes (such as DCFH-DA, MitoSOXRed); 3) Detection of mitochondrial oxygen consumption rate (OCR): Mitochondrial oxygen consumption rate is an important indicator reflecting mitochondrial function, and OCR can be measured using equipment such as the Seahorse XF analyzer; 4) Detection of ATP content: ATP is the main energy molecule in cells, and its content can reflect the energy production capacity of mitochondria. The content of intracellular ATP can be detected using methods such as the luciferase method; 5) Mitochondrial membrane potential. Mitochondrial membrane potential (MMP) detection: Changes in mitochondrial membrane potential (ΔΨm) can reflect the functional state of mitochondria, and ΔΨm can be detected using fluorescent dyes such as JC-1; 6) Mitochondrial DNA (mtDNA) analysis: Mutations and deletions in mitochondrial DNA are closely related to mitochondrial dysfunction, and mtDNA mutations and deletions can be analyzed using methods such as PCR and sequencing. However, the above methods still have certain drawbacks: morphological observation, ROS level detection, and OCR detection all rely to some extent on large instruments or complex equipment (such as flow cytometers, cell metabolism analyzers, etc.), which are costly; ATP production detection is easily affected by other metabolic pathways and cannot reflect mitochondrial damage independently; membrane potential detection only reflects the transient state and cannot continuously detect mitochondrial damage, and also requires complex equipment such as flow cytometers; mtDNA analysis mainly focuses on genetic variations and cannot monitor the physiological function of mitochondria.
[0004] Therefore, it is of great significance to develop a mitochondrial function detection method that does not require complex equipment, is simple to operate, cost-effective, and can continuously detect and dynamically evaluate mitochondrial function. Summary of the Invention
[0005] This invention aims to address at least one of the technical problems existing in the prior art. To this end, this invention proposes a method for detecting mitochondrial function and its application, as well as a mitochondrial function detection kit, aiming to solve the problems that current mitochondrial function detection methods require complex equipment, are costly, and cannot continuously detect mitochondrial function.
[0006] An embodiment of the first aspect of the present invention provides a method for detecting mitochondrial function, which determines mitochondrial function by detecting the level of mitochondrial DNA release into the cytoplasm after high-salt treatment.
[0007] The detection method according to the first aspect of the present invention has at least the following beneficial effects: The mitochondrial function detection method provided by the present invention determines the quality of mitochondrial function by detecting the release of mitochondrial DNA into the cytoplasm under high salt stimulation. The present invention utilizes the sensitive response of mitochondrial DNA to external stimuli (high salt) to directly detect mitochondrial DNA leakage, thereby determining the quality of mitochondrial function. This detection method does not require complex and expensive equipment such as O2K or flow cytometers; it can be completed with only conventional experimental equipment, resulting in low cost and suitability for large-scale detection. It is simple and convenient to operate, requiring minimal technical expertise, only high salt treatment and conventional DNA level detection methods (e.g., qPCR), making it economical and efficient. It has high sensitivity, allowing detection of early cellular stress responses through the detection of mitochondrial DNA release via qPCR. Furthermore, unlike traditional endpoint detection, the method of the present invention continuously detects the release of mitochondrial DNA, observing its temporal dynamics and persistence, thereby dynamically assessing and monitoring mitochondrial function.
[0008] In some embodiments of the present invention, the high-salt treatment is treatment with a 200-300 mM sodium chloride (NaCl) solution. For example, treatment can be performed with sodium chloride solutions of 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM, 280 mM, 290 mM, or 300 mM, or with any concentration of sodium chloride solution within the range of 200-210 mM, 210-220 mM, 220-230 mM, 230-240 mM, 240-250 mM, 250-260 mM, 260-270 mM, 270-280 mM, 280-290 mM, or 290-300 mM. Preferably, the high-salt treatment is treatment with a 200 mM sodium chloride solution.
[0009] In some embodiments of the present invention, the high-salt treatment time is 3–24 hours. However, this is not a limitation, and the high-salt treatment time can be set according to actual conditions. For example, if continuous monitoring of mitochondrial damage over 48 hours is required, the high-salt treatment time can be set to 3–48 hours; if continuous monitoring of mitochondrial damage over 72 hours is required, the high-salt treatment time can be set to 3–72 hours; if continuous monitoring of mitochondrial damage over 24–48 hours is required, the high-salt treatment time can be set to 24–48 hours; if continuous monitoring of mitochondrial damage over 48–72 hours is required, the high-salt treatment time can be set to 48–72 hours. And so on, the high-salt treatment time is related to the duration of mitochondrial function monitoring.
[0010] In some embodiments of the present invention, the method for detecting mitochondrial function includes the following steps:
[0011] S100 provides the cells to be tested;
[0012] S200. The cells to be tested are subjected to high salt treatment for a predetermined time, and then the cell pellet is collected by centrifugation.
[0013] S300: Add cell lysis buffer to the cell pellet to lyse the cells, then centrifuge twice and collect the supernatant and secondary pellet respectively.
[0014] S400: Extract total cellular DNA from the secondary precipitate;
[0015] S500. Detect the mitochondrial DNA content in the supernatant and the total cell DNA respectively, and calculate the ratio of the mitochondrial DNA content in the supernatant to the mitochondrial DNA content in the total cell DNA to obtain the amount of mitochondrial DNA released by the test cells under high salt treatment.
[0016] S600. Assess mitochondrial function based on the amount of mitochondrial DNA released from the test cells under high salt treatment.
[0017] In some embodiments of the present invention, assessing mitochondrial function based on the amount of mitochondrial DNA released by the test cells under high salt treatment specifically includes: after high salt treatment, if the amount of mitochondrial DNA released by the test cells is 2 to 6 times higher than the normal level, and the release time does not exceed 24 hours, the mitochondrial function of the test cells can be judged to be normal.
[0018] Specifically, after 3 hours of high-salt treatment, the amount of mitochondrial DNA released from the test cells was 2 to 6 times higher than the normal level.
[0019] Specifically, after 24 hours of high-salt treatment, the amount of mitochondrial DNA released from the test cells was consistent with the normal level.
[0020] Specifically, the normal level refers to the proportion of mitochondrial DNA in the cytoplasm of cells that have not undergone high-salt treatment to the total mitochondrial DNA content of the cell.
[0021] This invention discovers that under normal (good) mitochondrial function, cells stimulated with high salt for 3 hours exhibit significant mitochondrial DNA release (approximately 2-6 times higher than normal levels), and this release ceases after 24 hours. Therefore, this invention develops a detection method to assess mitochondrial function under high salt stimulation based on mitochondrial DNA leakage (the proportion of mitochondrial DNA released into the cytoplasm). The method calculates the amount of mitochondrial DNA released by the test cells under high salt treatment based on the proportion of mitochondrial DNA content in the supernatant (i.e., the content of mitochondrial DNA in the cytoplasm) to the total mitochondrial DNA content in the cell, and then assesses mitochondrial function accordingly. This method is simple to operate, requires no complex equipment, and is suitable for large-scale detection; it is economical and efficient, requiring only high salt treatment and qPCR detection, resulting in low cost; moreover, it allows for dynamic assessment, measuring the release time and persistence of mitochondrial DNA, rather than just as an endpoint detection.
[0022] In some embodiments of the present invention, the mitochondrial DNA content is detected by qPCR using primers specifically designed for detecting mitochondrial DNA.
[0023] Specifically, the qPCR detection steps and reagents used can follow conventional methods in this field, such as using commercially available qPCR detection kits.
[0024] In some embodiments of the present invention, the primers for specifically detecting mitochondrial DNA include primers for detecting the ND1 gene and / or the Dloop gene.
[0025] In some embodiments of the present invention, the primers for specifically detecting mitochondrial DNA include primers as shown in SEQ ID NO. 1-4.
[0026] mt-ND1-F:
[0027] SEQ ID NO.1:GAGCGATGGTGAGAGCTAAGGT
[0028] mt-ND1-R:
[0029] SEQ ID NO.2:CCCTAAAACCCGCCACATCT
[0030] mt-Dloop-F:
[0031] SEQ ID NO.3:CATCTGGTTCCTACTTCAGGG
[0032] mt-Dloop-R:
[0033] SEQ ID NO.4:TGAGTGGTTAATAGGGTGATAGA
[0034] In some specific embodiments of the present invention, the primers for detecting the mitochondrial DNA content by qPCR include primers as shown in SEQ ID NO.1-2.
[0035] In some specific embodiments of the present invention, the primers for detecting the mitochondrial DNA content by qPCR include primers as shown in SEQ ID NO. 3-4.
[0036] The ND1 and Dloop genes are coding genes on the mitochondrial genome and can be used to detect mitochondrial DNA copy number. After lysing and centrifuging the test cells, free mtDNA in the cytoplasm remains in the supernatant, while intact mitochondria and their mitochondrial genome (total mtDNA) precipitate. Therefore, by quantitative real-time analysis of the mitochondrial DNA copy number in the supernatant and precipitate, the level of mtDNA leakage can be assessed. In practical applications, any one pair of primers from ND1 or Dloop can be selected for detection, with the other pair used for auxiliary verification.
[0037] In some embodiments of the present invention, the test cells include peripheral blood mononuclear cells (PBMCs), bone marrow cells, spleen cells, etc., but are not limited to these. The detection method provided by the present invention can be applied to the detection of mitochondrial function in various cell types. Specifically, the test cells are peripheral blood mononuclear cells because PBMCs are easy to obtain and cause minimal damage.
[0038] In some embodiments of the present invention, in step S200, the high-salt treatment is a treatment with a 200-300 mM sodium chloride (NaCl) solution. For example, treatment can be performed with sodium chloride solutions of 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM, 280 mM, 290 mM, or 300 mM, or with any concentration of sodium chloride solution within the range of 200-210 mM, 210-220 mM, 220-230 mM, 230-240 mM, 240-250 mM, 250-260 mM, 260-270 mM, 270-280 mM, 280-290 mM, or 290-300 mM. Preferably, the high-salt treatment is a 200 mM sodium chloride solution treatment.
[0039] In some embodiments of the present invention, the predetermined time in step S200 is 3 to 24 hours. However, it is not limited to this; the high-salt treatment time can be set according to actual conditions. For example, if the mitochondrial damage is to be continuously detected within 48 hours, the predetermined time can be set to 3 to 48 hours; if the mitochondrial damage is to be continuously detected within 72 hours, the predetermined time can be set to 3 to 72 hours; if the mitochondrial damage is to be continuously detected within 24 to 48 hours, the predetermined time can be set to 24 to 48 hours; if the mitochondrial damage is to be continuously detected within 48 to 72 hours, the predetermined time can be set to 48 to 72 hours. And so on, the high-salt treatment time is related to the duration of mitochondrial function detection.
[0040] In some embodiments of the present invention, in step S200, the centrifugation conditions are: 300-500g, centrifugation for 5-10 minutes. Preferably, centrifugation at 300g for 5 minutes is used.
[0041] In some embodiments of the present invention, in step S300, the cell lysis buffer is formulated as follows: 150 mM NaCl, 50 mM HEPES, and 25 μg / ml Digitonin.
[0042] In some embodiments of the present invention, the conditions for the second centrifugation in step S300 are: 4°C, 10000–12000g, centrifugation for 15–20 min. Preferably, centrifugation at 10000g for 15 min is used.
[0043] In some embodiments of the present invention, in step S400, the method for extracting total cellular DNA can be any conventional approach in the art, such as using a commercially available total DNA extraction kit.
[0044] A second aspect of the present invention provides the application of the above-described method for detecting mitochondrial function in mitochondrial function assessment, wherein the application is for non-diagnostic or therapeutic purposes.
[0045] According to the second aspect of the present invention, the method for detecting mitochondrial function provides at least the following beneficial effects: The method determines the quality of mitochondrial function by detecting the release of mitochondrial DNA into the cytoplasm under high-salt stimulation. The present invention utilizes the sensitive response of mitochondrial DNA to external stimuli (high salt) to directly detect mitochondrial DNA leakage, thereby determining the quality of mitochondrial function. Applying the above method to mitochondrial function assessment is low-cost, requires no large-scale equipment, and is suitable for large-scale detection; it is simple and convenient to operate, requiring only high-salt treatment and conventional DNA level detection methods (e.g., qPCR), making it economical and efficient; it has high sensitivity, allowing detection of early cellular stress responses through the detection of mitochondrial DNA release via qPCR. Furthermore, unlike traditional endpoint detection, the method of the present invention continuously detects the release of mitochondrial DNA, observing its temporal dynamics and persistence, thereby dynamically assessing and monitoring mitochondrial function. The above scheme has broad application prospects: it can be used to detect the impact of high salt intake on individual health, especially for mitochondrial function assessment in the elderly and hypertensive patients.
[0046] Studies have shown that mtDNA release can serve as an important marker of mitochondrial damage. Once in the cytoplasm, mtDNA can activate the cGAS-STING pathway, triggering a type I interferon response. It can also activate pro-inflammatory factors such as IL-1β through the NLRP3 inflammasome, thereby inducing a chronic inflammatory response. Long-term mtDNA release is closely related to autoimmune diseases, cardiovascular diseases, and neurodegenerative diseases. This invention utilizes the sensitive response of mitochondrial DNA to external stimuli (high salt) to directly detect mtDNA leakage, thereby assessing the state of mitochondrial function.
[0047] According to a third aspect of the present invention, a mitochondrial function detection kit is provided, comprising primers for specifically detecting mitochondrial DNA and a high-salt solution, wherein the detection kit uses the above-described detection method to detect mitochondrial function.
[0048] In some embodiments of the present invention, the high-salt solution comprises a 200-300 mM sodium chloride (NaCl) solution, such as sodium chloride solutions of 200 mM, 210 mM, 220 mM, 230 mM, 240 mM, 250 mM, 260 mM, 270 mM, 280 mM, 290 mM, or 300 mM, or sodium chloride solutions of any concentration within the range of 200-210 mM, 210-220 mM, 220-230 mM, 230-240 mM, 240-250 mM, 250-260 mM, 260-270 mM, 270-280 mM, 280-290 mM, or 290-300 mM. Preferably, the high-salt solution is a 200 mM sodium chloride solution.
[0049] In some embodiments of the present invention, the primers for specifically detecting mitochondrial DNA include primers for detecting the ND1 gene and / or the Dloop gene.
[0050] In some embodiments of the present invention, the primers for specifically detecting mitochondrial DNA include primers as shown in SEQ ID NO. 1-4.
[0051] mt-ND1-F:
[0052] SEQ ID NO.1:GAGCGATGGTGAGAGCTAAGGT
[0053] mt-ND1-R:
[0054] SEQ ID NO.2:CCCTAAAACCCGCCACATCT
[0055] mt-Dloop-F:
[0056] SEQ ID NO.3:CATCTGGTTCCTACTTCAGGG
[0057] mt-Dloop-R:
[0058] SEQ ID NO.4:TGAGTGGTTAATAGGGTGATAGA
[0059] In some specific embodiments of the present invention, the primers for specifically detecting mitochondrial DNA include primers as shown in SEQ ID NO.1-2.
[0060] In some specific embodiments of the present invention, the primers for specifically detecting mitochondrial DNA include primers as shown in SEQ ID NO. 3-4.
[0061] In some embodiments of the present invention, the detection kit further includes cell lysis buffer, total cell DNA extraction reagent, and qPCR reaction reagent.
[0062] Specifically, the cell lysis buffer formulation is: 150mM NaCl, 50mM HEPES, and 25μg / ml Digitonin. However, it is not limited to this; other lysis buffer formulations can also be used as long as they can achieve the effect of lysing cells.
[0063] Specifically, conventional reagents in the field can be used for total cell DNA extraction, such as commercially available total cell DNA extraction reagents.
[0064] Specifically, conventional reagents used in the field can be employed for qPCR reactions, such as commercially available qPCR detection kits.
[0065] Other features and advantages of the invention will be set forth in the description which follows, and will be apparent in part from the description, or may be learned by practicing the invention. The objects and other advantages of the invention may be realized and obtained by means of the structures particularly pointed out in the description, claims, and drawings. Attached Figure Description
[0066] Figure 1 This is a schematic diagram illustrating the detection of mitochondrial DNA release levels in PBMCs under high-salt treatment using ND1 primers, as provided in an embodiment of the present invention.
[0067] Figure 2 This is a schematic diagram illustrating the detection of mitochondrial DNA release levels in PBMCs under high-salt treatment using Dloop primers, as provided in an embodiment of the present invention.
[0068] Figure 3 This is a schematic diagram illustrating the mitochondrial DNA release levels of PBMCs in different age groups under high-salt treatment, as provided in an embodiment of the present invention. Detailed Implementation
[0069] The following will describe the concept and technical effects of the present invention clearly and completely with reference to embodiments, so as to fully understand the purpose, features and effects of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are all within the scope of protection of the present invention.
[0070] In the description of this invention, the terms "one embodiment," "some embodiments," "illustrative embodiment," "example," "specific example," or "some examples," etc., refer to specific features, structures, materials, or characteristics described in connection with that embodiment or example, which are included in at least one embodiment or example of the invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples.
[0071] In the description of this invention, unless otherwise stated, the numerical range "a~b" represents a shortened representation of any combination of real numbers between a and b, where a and b are both real numbers. Unless otherwise stated, the various reaction or operation steps may be performed sequentially or not. Preferably, the reaction methods in this invention are performed sequentially.
[0072] Experimental methods in the following examples, unless otherwise specified, are generally performed under standard conditions or as recommended by the manufacturer. Unless otherwise specified, the materials and reagents used in these examples are commercially available.
[0073] Example 1: Isolation of PBMCs from Peripheral Blood
[0074] In this embodiment, PBMCs are isolated from peripheral blood for subsequent testing. The specific steps are as follows:
[0075] (1) Collect 5 mL of fresh peripheral blood (collection process in accordance with relevant regulations), anticoagulate with sodium citrate, and prepare for PBMC separation;
[0076] (2) Add 7 mL of lymphocyte separation medium (Lymphoprep) to the bottom of a clean 50 mL centrifuge tube. TM (07851, STEMCELL);
[0077] (3) After mixing the peripheral blood collected in (1) with an equal volume of PBS, slowly add it to the upper layer of the lymphocyte separation medium in (2), taking care to avoid mixing the liquid surface. Centrifuge at 800g at room temperature for 20 minutes with the centrifuge turned off.
[0078] (4) Gently aspirate the uppermost layer of plasma with a disposable pipette and discard it. Then, carefully aspirate the white cell layer on the separation solution with a 1000 μL pipette and transfer it to a clean 50 mL centrifuge tube.
[0079] (5) Wash the cells twice with 20 mL of PBS and resuspend them in 1 mL of RPMI 1640 medium containing 10% FBS;
[0080] (6) Take 20 μL of cell suspension, add an equal volume of 0.4% trypan blue for staining, mix well, then take 10 μL of the stained cell suspension and add it to the cell counting chamber. Place the counting chamber into the cell counter for live cell counting.
[0081] (7) Based on the counting results, use 1×10 6 Cells were cultured at a density of 1,000 cells / mL in a 37°C incubator containing 5% CO2 for subsequent operations.
[0082] Example 2: Detection of mitochondrial DNA release from PBMCs under high salt stimulation
[0083] Peripheral blood was collected from 6 healthy volunteers according to the method in Example 1, and PBMCs were isolated and cultured (the collection process complied with relevant regulations).
[0084] PBMCs isolated from each volunteer were divided into a control group (cells treated with 150mM NaCl), a high-salt group (cells treated with 200mM NaCl), and a D-mannitol group (cells treated with 100mM D-mannitol). Cytoplasm and total cellular DNA were collected 3 and 24 hours after treatment, respectively, and mtDNA (ND1, D-loop) was detected by qPCR.
[0085] The specific steps are as follows:
[0086] (1) After treating cells according to different groups and times, centrifuge at 300×g for 5 minutes and collect approximately 1×10⁻⁶ cell pellets. 6 indivual.
[0087] (2) Add 500 μL of lysis buffer to resuspend the cell pellet, mix by pipetting, and place on ice for 10 minutes for lysis, mixing several times during the process; the lysis buffer formula is: 150 mM NaCl, 50 mM HEPES, 25 μg / ml Digitonin (HY-N4000, MCE).
[0088] (3) Centrifuge at 4℃, 10000×g for 15 minutes, and collect the supernatant (cytoplasmic fraction);
[0089] (4) Extract total DNA from the precipitate after centrifugation using the GenStar Total DNA Purification Kit (D133-01);
[0090] (5) The content of mtDNA (cytoplasmic mtDNA) in the supernatant and the content of mtDNA (total mtDNA) in total DNA were detected by qPCR and expressed as the percentage of cytoplasmic mtDNA to total mtDNA.
[0091] The qPCR primers are as follows:
[0092] mt-ND1-F:
[0093] SEQ ID NO.1:GAGCGATGGTGAGAGCTAAGGT
[0094] mt-ND1-R:
[0095] SEQ ID NO.2:CCCTAAAACCCGCCACATCT
[0096] mt-Dloop-F:
[0097] SEQ ID NO.3:CATCTGGTTCCTACTTCAGGG
[0098] mt-Dloop-R:
[0099] SEQ ID NO.4:TGAGTGGTTAATAGGGTGATAGA
[0100] The results are as follows Figure 1 , 2 As shown in the figure. The purpose of setting up the D-mannitol group is that high salt leads to an increase in the osmotic pressure of the solution, and mannitol can be used as an osmotic pressure control to show that the leakage of mtDNA caused by high salt is not due to hyperosmosis, but rather a specific response to salt. As shown in the figure, compared with the control group and the D-mannitol group, the level of mitochondrial DNA in the cytoplasm of PBMCs was significantly increased after 3 hours of high salt stimulation (mtDNA release level) (p<0.001).
[0101] Example 3: Detection of mitochondrial DNA release from PBMCs in healthy young adults vs. older adults under high salt stimulation
[0102] Following the method in Example 1, peripheral blood was collected from 3 young volunteers (20-30 years old) and 3 elderly volunteers (over 50 years old), and PBMCs were isolated and cultured (the collection process complied with relevant regulations).
[0103] PBMCs isolated from each volunteer were divided into a control group (cells treated with 150mM NaCl) and a high-salt group (cells treated with 200mM NaCl). Cytoplasm and total cellular DNA were collected 3 and 24 hours after treatment, respectively, and mtDNA (D-loop) was detected by qPCR.
[0104] The specific steps are as follows:
[0105] (1) After treating cells according to different groups and times, centrifuge at 300×g for 5 minutes and collect approximately 1×10⁻⁶ cell pellets. 6 indivual.
[0106] (2) Add 500 μL of lysis buffer to resuspend the cell pellet, mix by pipetting, and place on ice for 10 minutes for lysis, mixing several times during the process; the lysis buffer formula is: 150 mM NaCl, 50 mM HEPES, 25 μg / ml Digitonin (HY-N4000, MCE).
[0107] (3) Centrifuge at 4℃, 10000×g for 15 minutes, and collect the supernatant (cytoplasmic fraction);
[0108] (4) Extract total DNA from the precipitate after centrifugation using the GenStar Total DNA Purification Kit (D133-01);
[0109] (5) The content of mtDNA (cytoplasmic mtDNA) in the supernatant and the content of mtDNA (total mtDNA) in total DNA were detected by qPCR and expressed as the percentage of cytoplasmic mtDNA to total mtDNA.
[0110] The qPCR primers are as follows:
[0111] mt-Dloop-F:
[0112] SEQ ID NO.3:CATCTGGTTCCTACTTCAGGG
[0113] mt-Dloop-R:
[0114] SEQ ID NO.4:TGAGTGGTTAATAGGGTGATAGA
[0115] The results are as follows Figure 3 As shown in the figure, in younger individuals, mitochondrial DNA release from PBMCs peaked at 3 hours after high salt stimulation and returned to near baseline levels after 24 hours; while in older individuals, mitochondrial DNA release from PBMCs remained elevated after high salt stimulation, persisting at high levels even after 6 hours (p<0.001). These results indicate that older individuals have decreased mitochondrial stress tolerance and a longer duration of mitochondrial DNA release.
[0116] The above is a detailed description of the preferred embodiments of this application. However, this application is not limited to the above embodiments. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of this application. All such equivalent modifications or substitutions are included within the scope defined by the claims of this application.
Claims
1. A method for detecting mitochondrial function, characterized in that, Mitochondrial function can be assessed by detecting the level of mitochondrial DNA released into the cytoplasm after high-salt treatment.
2. The method for detecting mitochondrial function according to claim 1, characterized in that, The high-salt treatment is a treatment with a 200-300 mM sodium chloride solution.
3. The method for detecting mitochondrial function according to claim 1, characterized in that, The high-salt treatment time is 3 to 24 hours.
4. The method for detecting mitochondrial function according to claim 1, characterized in that, Including the following steps: Provide the cells to be tested; The cells to be tested were subjected to high salt treatment for a predetermined time, and then the cell pellet was collected by centrifugation. Cell lysis buffer was added to the cell pellet to lyse the cells, followed by a second centrifugation, and the supernatant and secondary pellet were collected separately. Extract total cellular DNA from the secondary precipitate; The mitochondrial DNA content in the supernatant and the total cell DNA were detected separately, and the proportion of mitochondrial DNA content in the supernatant to the mitochondrial DNA content in the total cell DNA was calculated to obtain the amount of mitochondrial DNA released by the test cells under high salt treatment. Mitochondrial function was assessed based on the amount of mitochondrial DNA released from the test cells under high-salt treatment.
5. The method for detecting mitochondrial function according to claim 4, characterized in that, The assessment of mitochondrial function based on the amount of mitochondrial DNA released from the test cells under high salt treatment specifically includes: if, after high salt treatment, the amount of mitochondrial DNA released from the test cells is 2 to 6 times higher than the normal level, and the release time does not exceed 24 hours, the mitochondrial function of the test cells can be judged to be normal.
6. The method for detecting mitochondrial function according to claim 4, characterized in that, The mitochondrial DNA content was detected by qPCR using primers specifically designed for detecting mitochondrial DNA.
7. The method for detecting mitochondrial function according to claim 6, characterized in that, The primers for specifically detecting mitochondrial DNA include primers for detecting the ND1 gene and / or the Dloop gene.
8. The method for detecting mitochondrial function according to claim 4, characterized in that, The cells to be tested include peripheral blood mononuclear cells.
9. The application of the method for detecting mitochondrial function as described in any one of claims 1-8 in the assessment of mitochondrial function, wherein the application is for non-diagnostic or therapeutic purposes.
10. A mitochondrial function detection kit, characterized in that, The kit includes primers for specific detection of mitochondrial DNA and a high-salt solution, and the detection kit uses the detection method as described in any one of claims 1-8 to detect mitochondrial function.
